SARS-CoV-2 spike protein receptor-binding domain — Drug Target

All drugs that target SARS-CoV-2 spike protein receptor-binding domain — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Monoclonal antibody combination (neutralizing antibodies) · Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies) · Monoclonal antibody combination

Marketed (2)

• Lilly Bamlanivimab + Etesevimab · Erin McCreary · Monoclonal antibody combination (neutralizing antibodies) · Infectious Disease / Virology
  Bamlanivimab and etesevimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection.
• Casirivimab and Imdevimab Drug Combination · Mansoura University Hospital · Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies) · Infectious Disease / Virology
  This monoclonal antibody combination blocks the SARS-CoV-2 spike protein, preventing viral attachment and entry into host cells.

Phase 3 pipeline (2)

• BRII-196/BRII-198 · National Institute of Allergy and Infectious Diseases (NIAID) · Monoclonal antibody combination · Infectious Disease / Virology
  BRII-196/BRII-198 is a combination of two monoclonal antibodies that neutralize SARS-CoV-2 spike protein to prevent and treat COVID-19 infection.
• AZD7442 · AstraZeneca · Monoclonal antibody combination · Infectious Disease / Virology
  AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity.